Edition:
India

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

18.65USD
15 Dec 2017
Change (% chg)

$0.85 (+4.78%)
Prev Close
$17.80
Open
$17.80
Day's High
$18.80
Day's Low
$17.60
Volume
1,541,759
Avg. Vol
346,127
52-wk High
$25.70
52-wk Low
$7.80

Latest Key Developments (Source: Significant Developments)

Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Impax Laboratories Inc ::IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES.IMPAX LABORATORIES INC - COMPANY'S ANDA IS ELIGIBLE FOR FINAL APPROVAL UPON EXPIRATION OF MARKETING EXCLUSIVITY ON MAY 7, 2018.  Full Article

Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​
Wednesday, 22 Nov 2017 

Nov 21 (Reuters) - Impax Laboratories Inc :Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​.Impax Laboratories Inc - ‍also entered into amendment no. 1 with K2 Merger Sub Corporation & Amneal Pharmaceuticals Llc​.Impax Laboratories Inc - ‍in connection with closing, Holdco will be renamed Amneal Pharmaceuticals, Inc.​.Impax Laboratories - ‍in connection with pipe transaction, amneal desires to revise capital structure of new amneal to provide for class B-1 stock​.  Full Article

Impax Q3 adjusted earnings per share $0.23
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Impax Laboratories Inc :Impax reports third quarter 2017 results.Q3 adjusted earnings per share $0.23.Q3 GAAP loss per share $0.69.Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S.Q3 revenue $206.4 million versus I/B/E/S view $208.4 million.Impax Laboratories Inc - sees ‍2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47%​.Impax Laboratories Inc - sees ‍full year 2017 adjusted net income per share of $0.60 to $0.65​.FY2017 earnings per share view $0.70 -- Thomson Reuters I/B/E/S.Impax Laboratories Inc - sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Impax Laboratories Inc - ‍company narrows full year 2017 guidance​.Impax Laboratories Inc - ‍"while our Q3 results were in line with our expectations, we continue to navigate challenging generic market environment"​.Impax Laboratories Inc - ‍currently expect to complete closure of our Middlesex, New Jersey packaging facility by end of 2017, ahead of schedule​.Impax Laboratories Inc - ‍"we are in late-stage negotiations for sale of our Taiwan manufacturing facility​".Impax Laboratories - ‍if successful in selling Taiwan facility by end of Q1 of 2018, co could realize anticipated cost savings by end of 2018​.  Full Article

Impax gets FDA approval for generic Renvela tablets
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Impax Laboratories Inc :Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg.Impax Laboratories Inc - ‍impax has immediately initiated commercialization activities for a generic version of Renvela​.Impax Laboratories Inc - ‍sales of generic renvela are expected to benefit company's financial results this year​.  Full Article

IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Impax Laboratories Inc ::REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​.AMNEAL TO BE ENTITLED TO REIMBURSEMENT FOR UP TO $15 MILLION EXPENSES, IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES - SEC FILING.  Full Article

Drugmaker Amneal to combine with Impax Labs
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Impax Laboratories Inc :Amneal and Impax to combine.Transaction expected to generate $200 million of annual cost savings within three years​.Deal to be accretive to Impax's adjusted EPS within first 12 months​.Impax affirms 2017 financial guidance​.Amneal Holdings members to own about 75%, Impax shareholders to own about 25% of new co's pro forma shares on as converted basis​.Fy2017 earnings per share view $0.70, revenue view $800.8 million -- Thomson Reuters I/B/E/S.Combined company is expected to have 2018 pro forma adjusted EBITDA of approximately $700 million to $750 million​.Amneal's founders and co-chief executive officers, Chirag Patel & Chintu Patel, will serve as co-chairmen of combined co's board.‍Paul Bisaro, president and CEO of Impax, will serve as chief executive officer of combined company​.Co and ‍amneal Pharmaceuticals entered into a definitive business combination in an all-stock transaction​.Under terms of agreement, a new, publicly traded holding company, Amneal Pharmaceuticals Inc, will be formed​.Amneal Holdings members immediately prior to closing of transaction will receive non-economic, voting shares of Amneal Pharmaceuticals Inc​.Amneal Holdings members to be able to exchange membership units in Amneal Pharmaceuticals LLC for class A shares of Amneal Pharmaceuticals Inc​.Deal will be structured as "Up-C" deal with tax receivable agreement split 85% / 15% between Amneal Holdings members, Amneal Pharmaceuticals.  Full Article

Impax Laboratories announces launch of generic version of Metadate CD
Thursday, 22 Sep 2016 

Impax Laboratories Inc :Announced launch of a generic version of Metadate CD.  Full Article

Impax Laboratories issues nationwide recall for one lot of ODT
Saturday, 27 Aug 2016 

Impax Laboratories Inc : Impax laboratories Inc issues voluntary, nationwide recall for one lot of Lamotrigine Orally Disintegrating Tablet 200 mg due to the potential for 100 mg blister cards being packaged in 200 mg containers .Affected lot was distributed between June 13, 2016 and August 10, 2016 to wholesale distributors and retail pharmacies nationwide.  Full Article

Impax Laboratories reports Q2 GAAP loss per share $0.04
Tuesday, 9 Aug 2016 

Impax Laboratories Inc : Impax reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.21 . Q2 revenue $173 million . Q2 earnings per share view $0.32 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.04 . Sees FY 2016 adjusted earnings per share $1.57 to $1.70 . Q2 revenue view $223.7 million -- Thomson Reuters I/B/E/S . Sees FY 2016 capital expenditures of approximately $40 million . Sees FY 2016 adjusted gross margins as a percent of total revenue are expected to be in low 50% range . Sees FY 2016 total company revenues of approximately $900 million to $940 million .FY2016 earnings per share view $1.77, revenue view $994.4 million -- Thomson Reuters I/B/E/S.  Full Article

Impax Labs says co, Teva USA to terminate all rights and obligations of each party with respect to Methylphenidate HCl ER
Tuesday, 21 Jun 2016 

Impax Laboratories Inc :Co, Teva USA agreed to terminate all rights and obligations of each party with respect to Methylphenidate HCl ER.  Full Article

BRIEF-Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules

* IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES